Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 64

1.

Circulating tumor DNA alterations in patients with metastatic castration-resistant prostate cancer.

Sonpavde G, Agarwal N, Pond GR, Nagy RJ, Nussenzveig RH, Hahn AW, Sartor O, Gourdin TS, Nandagopal L, Ledet EM, Naik G, Armstrong AJ, Wang J, Bilen MA, Gupta S, Grivas P, Pal SK, Lanman RB, Talasaz A, Lilly MB.

Cancer. 2019 May 1;125(9):1459-1469. doi: 10.1002/cncr.31959. Epub 2019 Jan 8.

PMID:
30620391
2.

Advanced glycation end products are elevated in estrogen receptor-positive breast cancer patients, alter response to therapy, and can be targeted by lifestyle intervention.

Walter KR, Ford ME, Gregoski MJ, Kramer RM, Knight KD, Spruill L, Nogueira LM, Krisanits BA, Phan V, La Rue AC, Lilly MB, Ambs S, Chan K, Turner TF, Varner H, Singh S, Uribarri J, Garrett-Mayer E, Armeson KE, Hilton EJ, Clair MJ, Taylor MH, Abbott AM, Findlay VJ, Peterson LL, Magwood G, Turner DP.

Breast Cancer Res Treat. 2019 Feb;173(3):559-571. doi: 10.1007/s10549-018-4992-7. Epub 2018 Oct 27.

3.

Development of cell-penetrating bispecific antibodies targeting the N-terminal domain of androgen receptor for prostate cancer therapy.

Goicochea NL, Garnovskaya M, Blanton MG, Chan G, Weisbart R, Lilly MB.

Protein Eng Des Sel. 2017 Dec 1;30(12):785-793. doi: 10.1093/protein/gzx058.

PMID:
29228299
4.

Ablation of PI3K blocks BCR-ABL leukemogenesis in mice, and a dual PI3K/mTOR inhibitor prevents expansion of human BCR-ABL+ leukemia cells.

Kharas MG, Janes MR, Scarfone VM, Lilly MB, Knight ZA, Shokat KM, Fruman DA.

J Clin Invest. 2017 Jun 1;127(6):2438. doi: 10.1172/JCI95182. Epub 2017 Jun 1. No abstract available.

5.

Flavokawain A induces deNEDDylation and Skp2 degradation leading to inhibition of tumorigenesis and cancer progression in the TRAMP transgenic mouse model.

Li X, Yokoyama NN, Zhang S, Ding L, Liu HM, Lilly MB, Mercola D, Zi X.

Oncotarget. 2015 Dec 8;6(39):41809-24. doi: 10.18632/oncotarget.6166.

6.

The Sphingosine Kinase 2 Inhibitor ABC294640 Reduces the Growth of Prostate Cancer Cells and Results in Accumulation of Dihydroceramides In Vitro and In Vivo.

Venant H, Rahmaniyan M, Jones EE, Lu P, Lilly MB, Garrett-Mayer E, Drake RR, Kraveka JM, Smith CD, Voelkel-Johnson C.

Mol Cancer Ther. 2015 Dec;14(12):2744-52. doi: 10.1158/1535-7163.MCT-15-0279. Epub 2015 Oct 22.

7.

SWOG S0925: A Randomized Phase II Study of Androgen Deprivation Combined With Cixutumumab Versus Androgen Deprivation Alone in Patients With New Metastatic Hormone-Sensitive Prostate Cancer.

Yu EY, Li H, Higano CS, Agarwal N, Pal SK, Alva A, Heath EI, Lam ET, Gupta S, Lilly MB, Inoue Y, Chi KN, Vogelzang NJ, Quinn DI, Cheng HH, Plymate SR, Hussain M, Tangen CM, Thompson IM Jr.

J Clin Oncol. 2015 May 10;33(14):1601-8. doi: 10.1200/JCO.2014.59.4127. Epub 2015 Apr 6.

8.

Generation of "virtual" control groups for single arm prostate cancer adjuvant trials.

Jia Z, Lilly MB, Koziol JA, Chen X, Xia XQ, Wang Y, Skarecky D, Sutton M, Sawyers A, Ruckle H, Carpenter PM, Wang-Rodriguez J, Jiang J, Deng M, Pan C, Zhu JG, McLaren CE, Gurley MJ, Lee C, McClelland M, Ahlering T, Kattan MW, Mercola D.

PLoS One. 2014 Jan 21;9(1):e85010. doi: 10.1371/journal.pone.0085010. eCollection 2014.

9.

Health care services use in assisted living: a time series analysis.

McGrail KM, Lilly MB, McGregor MJ, Broemeling AM, Salomons K, Peterson S, McKendry R, Barer ML.

Can J Aging. 2013 Jun;32(2):173-83. doi: 10.1017/S0714980813000159. Epub 2013 May 23.

PMID:
23701920
10.

A phase II trial of dasatinib in patients with metastatic castration-resistant prostate cancer treated previously with chemotherapy.

Twardowski PW, Beumer JH, Chen CS, Kraft AS, Chatta GS, Mitsuhashi M, Ye W, Christner SM, Lilly MB.

Anticancer Drugs. 2013 Aug;24(7):743-53. doi: 10.1097/CAD.0b013e328361feb0.

11.

The fiscal impact of informal caregiving to home care recipients in Canada: how the intensity of care influences costs and benefits to government.

Jacobs JC, Lilly MB, Ng C, Coyte PC.

Soc Sci Med. 2013 Mar;81:102-9. doi: 10.1016/j.socscimed.2012.12.015. Epub 2013 Jan 5.

PMID:
23347496
12.
13.

Plasma-derived exosomal survivin, a plausible biomarker for early detection of prostate cancer.

Khan S, Jutzy JM, Valenzuela MM, Turay D, Aspe JR, Ashok A, Mirshahidi S, Mercola D, Lilly MB, Wall NR.

PLoS One. 2012;7(10):e46737. doi: 10.1371/journal.pone.0046737. Epub 2012 Oct 16.

14.

Efficacy of the investigational mTOR kinase inhibitor MLN0128/INK128 in models of B-cell acute lymphoblastic leukemia.

Janes MR, Vu C, Mallya S, Shieh MP, Limon JJ, Li LS, Jessen KA, Martin MB, Ren P, Lilly MB, Sender LS, Liu Y, Rommel C, Fruman DA.

Leukemia. 2013 Mar;27(3):586-94. doi: 10.1038/leu.2012.276. Epub 2012 Oct 1.

15.

Stakeholder perspectives on transitions of nursing home residents to hospital emergency departments and back in two Canadian provinces.

Robinson CA, Bottorff JL, Lilly MB, Reid C, Abel S, Lo M, Cummings GG.

J Aging Stud. 2012 Dec;26(4):419-27. doi: 10.1016/j.jaging.2012.06.001. Epub 2012 Jun 23.

16.

Kava components down-regulate expression of AR and AR splice variants and reduce growth in patient-derived prostate cancer xenografts in mice.

Li X, Liu Z, Xu X, Blair CA, Sun Z, Xie J, Lilly MB, Zi X.

PLoS One. 2012;7(2):e31213. doi: 10.1371/journal.pone.0031213. Epub 2012 Feb 9.

17.

Can we move beyond burden and burnout to support the health and wellness of family caregivers to persons with dementia? Evidence from British Columbia, Canada.

Lilly MB, Robinson CA, Holtzman S, Bottorff JL.

Health Soc Care Community. 2012 Jan;20(1):103-12. doi: 10.1111/j.1365-2524.2011.01025.x. Epub 2011 Aug 18.

PMID:
21851447
18.

Sphingolipid-based drugs selectively kill cancer cells by down-regulating nutrient transporter proteins.

Romero Rosales K, Singh G, Wu K, Chen J, Janes MR, Lilly MB, Peralta ER, Siskind LJ, Bennett MJ, Fruman DA, Edinger AL.

Biochem J. 2011 Oct 15;439(2):299-311. doi: 10.1042/BJ20110853.

19.

Differential expression of peroxiredoxins in prostate cancer: consistent upregulation of PRDX3 and PRDX4.

Basu A, Banerjee H, Rojas H, Martinez SR, Roy S, Jia Z, Lilly MB, De León M, Casiano CA.

Prostate. 2011 May 15;71(7):755-65. doi: 10.1002/pros.21292. Epub 2010 Oct 28.

20.

Do they care too much to work? The influence of caregiving intensity on the labour force participation of unpaid caregivers in Canada.

Lilly MB, Laporte A, Coyte PC.

J Health Econ. 2010 Dec;29(6):895-903. doi: 10.1016/j.jhealeco.2010.08.007. Epub 2010 Sep 22.

PMID:
20864197
21.

Regulation of Skp2 levels by the Pim-1 protein kinase.

Cen B, Mahajan S, Zemskova M, Beharry Z, Lin YW, Cramer SD, Lilly MB, Kraft AS.

J Biol Chem. 2010 Sep 17;285(38):29128-37. doi: 10.1074/jbc.M110.137240. Epub 2010 Jul 27.

22.

p53-dependent induction of prostate cancer cell senescence by the PIM1 protein kinase.

Zemskova M, Lilly MB, Lin YW, Song JH, Kraft AS.

Mol Cancer Res. 2010 Aug;8(8):1126-41. doi: 10.1158/1541-7786.MCR-10-0174. Epub 2010 Jul 20.

23.

Dasatinib 140 mg once daily versus 70 mg twice daily in patients with Ph-positive acute lymphoblastic leukemia who failed imatinib: Results from a phase 3 study.

Lilly MB, Ottmann OG, Shah NP, Larson RA, Reiffers JJ, Ehninger G, Müller MC, Charbonnier A, Bullorsky E, Dombret H, Brigid Bradley-Garelik M, Zhu C, Martinelli G.

Am J Hematol. 2010 Mar;85(3):164-70. doi: 10.1002/ajh.21615.

24.

Effective and selective targeting of leukemia cells using a TORC1/2 kinase inhibitor.

Janes MR, Limon JJ, So L, Chen J, Lim RJ, Chavez MA, Vu C, Lilly MB, Mallya S, Ong ST, Konopleva M, Martin MB, Ren P, Liu Y, Rommel C, Fruman DA.

Nat Med. 2010 Feb;16(2):205-13. doi: 10.1038/nm.2091. Epub 2010 Jan 13.

25.

PIM-1 kinase expression in adipocytic neoplasms: diagnostic and biological implications.

Nga ME, Swe NN, Chen KT, Shen L, Lilly MB, Chan SP, Salto-Tellez M, Das K.

Int J Exp Pathol. 2010 Feb;91(1):34-43. doi: 10.1111/j.1365-2613.2009.00673.x. Epub 2009 Oct 28.

26.

Docetaxel-induced prostate cancer cell death involves concomitant activation of caspase and lysosomal pathways and is attenuated by LEDGF/p75.

Mediavilla-Varela M, Pacheco FJ, Almaguel F, Perez J, Sahakian E, Daniels TR, Leoh LS, Padilla A, Wall NR, Lilly MB, De Leon M, Casiano CA.

Mol Cancer. 2009 Aug 28;8:68. doi: 10.1186/1476-4598-8-68.

27.

PIM1 protein kinase regulates PRAS40 phosphorylation and mTOR activity in FDCP1 cells.

Zhang F, Beharry ZM, Harris TE, Lilly MB, Smith CD, Mahajan S, Kraft AS.

Cancer Biol Ther. 2009 May;8(9):846-53. Epub 2009 May 18.

PMID:
19276681
28.

Potential roles for the PIM1 kinase in human cancer - a molecular and therapeutic appraisal.

Shah N, Pang B, Yeoh KG, Thorn S, Chen CS, Lilly MB, Salto-Tellez M.

Eur J Cancer. 2008 Oct;44(15):2144-51. doi: 10.1016/j.ejca.2008.06.044. Epub 2008 Aug 18. Review.

PMID:
18715779
29.

Ablation of PI3K blocks BCR-ABL leukemogenesis in mice, and a dual PI3K/mTOR inhibitor prevents expansion of human BCR-ABL+ leukemia cells.

Kharas MG, Janes MR, Scarfone VM, Lilly MB, Knight ZA, Shokat KM, Fruman DA.

J Clin Invest. 2008 Sep;118(9):3038-50. doi: 10.1172/JCI33337. Erratum in: J Clin Invest. 2017 Jun 1;127(6):2438.

31.

Negative regulation of Pim-1 protein kinase levels by the B56beta subunit of PP2A.

Ma J, Arnold HK, Lilly MB, Sears RC, Kraft AS.

Oncogene. 2007 Aug 2;26(35):5145-53. Epub 2007 Feb 12.

PMID:
17297438
32.

Characterization of a potent and selective small-molecule inhibitor of the PIM1 kinase.

Holder S, Zemskova M, Zhang C, Tabrizizad M, Bremer R, Neidigh JW, Lilly MB.

Mol Cancer Ther. 2007 Jan;6(1):163-72. Epub 2007 Jan 11.

33.

Gene expression profiling in R-flurbiprofen-treated prostate cancer: R-Flurbiprofen regulates prostate stem cell antigen through activation of AKT kinase.

Zemskova M, Wechter W, Bashkirova S, Chen CS, Reiter R, Lilly MB.

Biochem Pharmacol. 2006 Nov 15;72(10):1257-67. Epub 2006 Sep 1.

PMID:
16949054
35.

Pim family kinases enhance tumor growth of prostate cancer cells.

Chen WW, Chan DC, Donald C, Lilly MB, Kraft AS.

Mol Cancer Res. 2005 Aug;3(8):443-51.

36.

Diphtheria toxin conjugate therapy of cancer.

Frankel AE, Powell BL, Lilly MB.

Cancer Chemother Biol Response Modif. 2002;20:301-13. Review.

PMID:
12703211
37.

Pim-1 protein kinase is nuclear in Burkitt's lymphoma: nuclear localization is necessary for its biologic effects.

Ionov Y, Le X, Tunquist BJ, Sweetenham J, Sachs T, Ryder J, Johnson T, Lilly MB, Kraft AS.

Anticancer Res. 2003 Jan-Feb;23(1A):167-78.

PMID:
12680209
38.
39.
42.

Pentoxifylline inhibits tumor necrosis factor-alpha-mediated cytotoxicity and cytostasis in L929 murine fibrosarcoma cells.

Takahashi GW, Montgomery RB, Stahl WL, Crittenden CA, Valentine MA, Thorning DR, Andrews DF 3rd, Lilly MB.

Int J Immunopharmacol. 1994 Sep;16(9):723-36.

PMID:
7806430
43.
44.

Effect of granulocyte-macrophage colony-stimulating factor and interleukin-3 on interleukin-8 production by human neutrophils and monocytes.

Takahashi GW, Andrews DF 3rd, Lilly MB, Singer JW, Alderson MR.

Blood. 1993 Jan 15;81(2):357-64.

PMID:
7678512
46.

Hyperthermia of pet animal tumours with self-regulating ferromagnetic thermoseeds.

Brezovich IA, Lilly MB, Meredith RF, Weppelmann B, Henderson RA, Brawner W Jr, Salter MM.

Int J Hyperthermia. 1990 Jan-Feb;6(1):117-30.

PMID:
2299225
47.

Human marrow stromal cells: response to interleukin-6 (IL-6) and control of IL-6 expression.

Nemunaitis J, Andrews DF, Mochizuki DY, Lilly MB, Singer JW.

Blood. 1989 Nov 1;74(6):1929-35.

PMID:
2679911
49.

Varied differentiation responses of human leukemias to bryostatin 1.

Kraft AS, William F, Pettit GR, Lilly MB.

Cancer Res. 1989 Mar 1;49(5):1287-93.

50.

Differential staining of neutrophils and monocytes: surface and cytoplasmic iron-binding proteins.

Barton JC, Parmley RT, Butler TW, Williamson SE, Lilly MB, Gualtieri RJ, Heck LW Jr.

Histochem J. 1988 Mar;20(3):147-55.

PMID:
2457567

Supplemental Content

Loading ...
Support Center